Examining Treatments for Thyroid Cancer: Targeted Therapy vs. Chemotherapy

Recruiting · Phase 3 · Refractory Differentiated Thyroid Gland Carcinoma · 32 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This trial looks at how well cabozantinib works compared to a combination of dabrafenib and trametinib for patients with a type of thyroid cancer that hasn't responded to earlier treatments. The goal is to find out which option is safer and more effective for patients with a specific mutation called BRAF V600E. Both treatments aim to help slow down or stop the growth of the cancer.

This is a Phase 3 trial, meaning it is looking at how well the treatments work and their safety. The trial is FDA-regulated and aims to include about 264 participants.

Who can join

This trial is open to men and women aged 18 and older. Participants must have thyroid cancer with the BRAF V600E mutation and have already tried other treatments. They should be in good enough health to participate. The trial team will check to confirm if someone is eligible to join.

Condition

Refractory Differentiated Thyroid Gland Carcinoma

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants will be randomly placed in one of two groups. In one group, patients will take dabrafenib and trametinib for 28 days at a time. In the other group, patients will take cabozantinib for the same length of time. Everyone will have regular check-ups, including scans and blood tests, to monitor their health throughout the study.